Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin HCl for non-small cell lung cancer–related cachexia (Phase III)
2010-023648-34Phase 3Completed
- Sponsor
- Helsinn Therapeutics (U.S.), Inc.
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS), non-small cell lung cancer (NSCLC) and anorexia nervosa (AN) comparing Anamorelin with Placebo (2 arms). Primary endpoints: Lean Body Mass change from baseline and Change in body weight. Started Jun 2011; status: completed.
02
Drugs
anamorelin
03
Conditions
cancer anorexia-cachexia syndrome (CACS)non-small cell lung cancer (NSCLC)anorexia nervosa (AN)
Beyond the preview
Go deeper on 2010-023648-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023648-34.